Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors

GlobeNewswire April 8, 2022

Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress

GlobeNewswire March 31, 2022

Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022

GlobeNewswire March 24, 2022

Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research

GlobeNewswire March 8, 2022

Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing

GlobeNewswire February 9, 2022

Affimed to Present at Upcoming Investor Events

GlobeNewswire February 8, 2022

Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update

GlobeNewswire January 6, 2022

Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 13, 2021

Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

GlobeNewswire December 9, 2021

Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's Anti-PD-L1 Checkpoint Inhibitor Atezolizumab

GlobeNewswire December 8, 2021

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

GlobeNewswire November 22, 2021

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

GlobeNewswire November 12, 2021

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

GlobeNewswire November 10, 2021

Affimed to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2021

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

GlobeNewswire November 8, 2021

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

GlobeNewswire November 4, 2021

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13

GlobeNewswire November 4, 2021

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

GlobeNewswire October 29, 2021

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire October 1, 2021